I Plan Nacional de Accesibilidad 2004-2012

El I Plan Nacional de Accesibilidad 2004-2012 (PNdA) es el mecanismo por el cual la Administración General del Estado se propone acometer de forma ordenada y conjunta con otras administraciones y entidades, la transformación de entornos, servicios y productos, para hacerlos plenamente accesibles a todas las personas, especialmente a aquellas con alguna discapacidad. Por ello la exigencia de desarrollo del Plan surge del articulado de una ley, la Ley 51/2003 sobre igualdad de oportunidades, no discriminación y accesibilidad universal de las personas con discapacidad. Su plazo de ejecución comprende hasta el año 2012.

I Plan Nacional de Accesibilidad 2004-2012: Informe de aplicación. Memoria final

Para arrancar y poner en práctica el Plan se ha considerado la necesidad de desarrollar una “hoja de ruta” (Informe de Puesta en Marcha y Aplicación) de cada una de las acciones consideradas más prioritarias en el primer trienio, a modo de guía para su implementación.

First report of Ascarophis Van Beneden, 1871: A. Brasiliensis n.sp. (Nematoda, Ascarophidinae) and Procamallanus (Spirocamallanus) Pereira/Annereaux, 1946 (Nematoda, Procamallaninae) in South America

Ascarophis brasiliensis recovered from the stomach of Trachinotus carolinus (L. 1766), is proposed as a new species and Procamallanus (Spirocamallanus) pereirai Annereaux, 1946 is redescribed from a new host: Paralonchurus brasiliensis (Steind., 1875). A. brasiliensis is more closely related to A. crassicolis Dollfus & Campana-Rouget, 1956, from which it differs mainly by the absence of cervical cuticular expansion and size of the eggs. The new species is also compared to A. cooperi johnston & Mawson, 1945 and A. girellae (Yamaguti, 1935) Campana-rouget, 1955. The validity of the proposed species is discussed.

Jordi Sabater Pi

Biografia del Doctor Jordi Sabater Pi, pioner mundial en l’estudi dels primats i dels amfibis africans.

Evaluation de la campagne Break The Chain 2012

L'Office fédéral de la santé publique (OFSP) a mandaté l'Institut universitaire de médecine sociale et préventive (IUMSP) afin d'évaluer la campagne nationale « Break The Chain » réalisée en avril 2012. Il s'agit d'une campagne de prévention du VIH/sida s'adressant exclusivement aux hommes ayant des rapports sexuels avec des hommes (HSH). Elle a été mise en oeuvre par le Checkpoint Zürich et le Checkpoint Genève avec l'appui de l'Aide suisse contre le sida (ASS) sur mandat de l'OFSP.

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases.

The process to develop a guideline in a European setting remains a challenge. The ESCMID Fungal Infection Study Group (EFISG) successfully achieved this endeavour. After two face-to-face meetings, numerous telephone conferences, and email correspondence, an ESCMID task force (basically composed of members of the Society's Fungal Infection Study Group, EFISG) finalized the ESCMID diagnostic and management/therapeutic guideline for Candida diseases. By appreciating various patient populations at risk for Candida diseases, four subgroups were predefined, mainly ICU patients, paediatric, HIV/AIDS and patients with malignancies including haematopoietic stem cell transplantation. Besides treatment recommendations, the ESCMID guidelines provide guidance for diagnostic procedures. For the guidelines, questions were formulated to phrase the intention of a given recommendation, for example, outcome. The recommendation was the clinical intervention, which was graded by a score of A-D for the 'Strength of a recommendation'. The 'level of evidence' received a score of I-III. The author panel was approved by ESCMID, European Organisation for Research and Treatment of Cancer, European Group for Blood and Marrow Transplantation, European Society of Intensive Care Medicine and the European Confederation of Medical Mycology. The guidelines followed the framework of GRADE and Appraisal of Guidelines, Research, and Evaluation. The drafted guideline was presented at ECCMID 2011 and points of discussion occurring during that meeting were incorporated into the manuscripts. These ESCMID guidelines for the diagnosis and management of Candida diseases provide guidance for clinicians in their daily decision-making process.

Embolie pulmonaire aiguë en 2012 (développements technologiques en scanner, angio-IRM).

Objectifs: Connaître les derniers développements techniques dans l'exploration de l'embolie pulmonaire aigue en imagerie (scanner et IRM). Connaître l'intérêt de la probabilité clinique pré-test dans l'indication de l'imagerie. Savoir faire une interprétation intégrée du scanner dans de l'embolie pulmonaire aiguë. Connaître chez les particularités de réalisation d'un examen chez la femme enceinte. Messages à retenir: Le scanner reste indiqué si les D-dimers sont négatifs et la probabilité clinique pré-test d'une embolie pulmonaire aiguë est élevée. Le scanner a une valeur diagnostique mais aussi une valeur pronostique dans la stratification du risque d'événement fatal chez les patients porteurs d'une embolie pulmonaire aiguë. Résumé: Durant la dernière décennie, l'imagerie en coupe s'est imposée comme moyen diagnostique incontournable dans l'embolie pulmonaire aiguë (EPA). Les nouveaux développements techniques ainsi que les récentes études ont contribué à mieux définir la valeur diagnostique du scanner et de l'IRM. En particulier, trois questions méritent d'être discutées : La probabilité clinique pré-test a-t-elle une importance dans l'indication de l'imagerie? ; (2) Faut-il synchroniser le scanner au rythme cardiaque devant une suspicion d'EPA ? ; (3) Quelles précautions faut-il prendre chez la femme enceinte ? Par ailleurs, La valeur pronostique du scanner mérite d'être connue et utilisée à bon escient.

Neurologie [2012: news in neurology].

In 2012, intramuscular midazolam appears as effective as intravenous lorezepam for the first line treatment of convulsive status epilepticus. Perampanel, a new anti-epileptic drug, will be soon available. Two oral treatments are now available for stroke prevention in atrial fibrillation setting. The methylphenidate and the Tai Chi could increase the walk capacity of patients suffering from Parkinson disease. A comprehensive cardiac work-up is essential for some congenital myopathy. A new drug against migraine seems free from vasoconstrictive effect. Antioxidants are harmful in Alzheimer disease. Some oral medication will be available for multiple sclerosis.

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the prevention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin ± Lactobacillus (B-II). The treatment of IC in neonates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system. Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafungin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole (A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B (A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used.